Apellis Pharmaceuticals, Inc. (APLS) Misses Q3 EPS by 17c
Tweet
Share
E-mailGet Alerts APLS Hot Sheet
Join SI Premium – FREE
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q3 EPS of ($0.46), $0.17 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $196.83 million versus the consensus estimate of $200.09 million.
For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- Independence Realty Trust (IRT) files mixed shelf
- MIND Technology (MIND) Misses Q1 EPS by 5c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
